跳至主要内容
临床试验/NCT00800514
NCT00800514撤回不适用

Amantadine and Temporal Discrimination in Patients With Traumatic Brain Injury

Wake Forest University Health Sciences1 个研究点 分布在 1 个国家开始时间: 2009年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
撤回
试验地点
1
主要终点
The primary outcome measure is the Interval Bisection Timing Task.

研究概览

简要总结

The study will explore the neurocognitive effect of four weeks of treatment with amantadine versus placebo in patients with traumatic brain injury using the Interval Bisection Timing Task. Approximately 16 individuals with traumatic brain injury are expected to participate in this study. Subject participation is expected to last up to 8 weeks with 16 study visits.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Crossover
主要目的
Basic Science
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18 to 55 inclusive. History of post-MVA close head TBI. Female subjects must use an acceptable method of contraception during entire study. Acceptable methods of contraception are: history of surgical sterility, postmenopausal status, hormonal contraceptives, or accepted barrier devices (i.e., male/female condom, diaphragm, cervical cap, intrauterine device).

排除标准

  • Current or past history of major psychiatric disorder (schizophrenia, bipolar disorder, major depressive disorder)
  • Substance use disorder
  • Current or past history of serious chronic medical condition (pulmonary (lung), cardiovascular (heart), hepato-renal (liver-kidney) disease, diabetes)
  • Smoking one or more packs of cigarettes per day
  • If you are pregnant or breastfeeding, or plan to become pregnant during the study

研究组 & 干预措施

active

Experimental

干预措施: amantadine (Drug)

结局指标

主要结局

The primary outcome measure is the Interval Bisection Timing Task.

时间窗: 12 -16 months

次要结局

  • The secondary efficacy measure is the Barrett Impulsiveness Scale (BIS-11).(12-16 moths)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验